Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Biomerica, Inc. (BMRA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.3900+0.2300 (+5.53%)
At close: 04:00PM EST
4.4500 +0.06 (+1.37%)
After hours: 06:02PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close4.1600
Open4.1300
Bid4.1600 x 800
Ask4.4500 x 1100
Day's Range4.1300 - 4.4400
52 Week Range3.3000 - 8.1500
Volume101,139
Avg. Volume246,398
Market Cap54.92M
Beta (5Y Monthly)-0.63
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Biomerica Reports Record Financial Results for Fiscal Second Quarter ended November 30, 2021

    Revenues up 239% over prior year fiscal second quarter Customer orders backlog of over $4.0 million at November 30, 2021 Walmart began in-store and online sales of Biomerica’s EZ Detect™ Colon Disease Test during fiscal second quarter InFoods® IBS endpoint trial is complete, topline trial results expected by the end of January IRVINE, Calif., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical products, today reported its second

  • GlobeNewswire

    Biomerica Announces Preliminary Second Quarter Revenue Increase of Approximately 238%, to Approximately $4.6 Million

    InFoods® IBS Clinical Trial on Track for Completion in December with Topline Results Expected to be Announced in January, 2022. IRVINE, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) today announced certain preliminary financial results for the second fiscal quarter ended November 30, 2021. All figures in this release are approximate due to the preliminary nature of this announcement. For the second quarter of fiscal 2022, ended November 30, 2021, Biomer

  • GlobeNewswire

    Biomerica Forms Scientific Advisory Board for Colorectal Cancer Screening

    Chaired by Dr. Brooks Cash, Chief of Gastroenterology and Hepatology at the University of Texas Health Center at HoustonScientific Advisory Board to guide on programs to screen and test patients in US and other countries where colorectal cancer screening is limited due to cost or insufficient laboratory infrastructure Biomerica’s two-minute at home test detects fecal occult (hidden) blood, an early warning sign of colorectal cancerAt home test is now available at Walmart and other retailers IRVI

Advertisement
Advertisement